(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.19%.
Werewolf Therapeutics's earnings in 2026 is -$34,613,000.On average, 5 Wall Street analysts forecast HOWL's earnings for 2026 to be -$47,753,442, with the lowest HOWL earnings forecast at -$60,486,398, and the highest HOWL earnings forecast at -$37,251,184. On average, 4 Wall Street analysts forecast HOWL's earnings for 2027 to be -$39,161,127, with the lowest HOWL earnings forecast at -$47,150,814, and the highest HOWL earnings forecast at -$30,107,121.
In 2028, HOWL is forecast to generate -$44,118,232 in earnings, with the lowest earnings forecast at -$42,388,105 and the highest earnings forecast at -$45,415,827.